(ACLS) Axcelis Technologies - NASDAQ
Sector: Technology | Industry: Semiconductor Equipment & Materials | Exchange: NASDAQ (USA) | Market Cap: 4.523m USD | Total Return: 122.5% in 12m
Avg Turnover: 78.3M
EPS Trend: -85.8%
Qual. Beats: 0
Rev. Trend: -86.6%
Qual. Beats: 0
Warnings
Fakeout Below Avwap Earnings
Tailwinds
No distinct edge detected
Axcelis Technologies (ACLS) specializes in the design and manufacture of ion implantation systems, a critical stage in the semiconductor fabrication process where dopants are introduced into silicon wafers to alter electrical properties. The company supports its hardware through a comprehensive aftermarket segment, providing maintenance, upgrades, and spare parts to chip manufacturers globally.
The semiconductor equipment sector is characterized by high barriers to entry due to the extreme precision and capital intensity required for ion implantation technology. As chip architectures become more complex, particularly in power electronics and image sensors, the demand for specialized high-energy and high-current implanters remains a key driver for the business model.
Investors can further evaluate these industry trends and specific company metrics on ValueRay.
Headquartered in Beverly, Massachusetts, Axcelis operates via a direct sales model across the United States, Europe, and Asia Pacific. Founded in 1978, the firm maintains a long-standing position within the Semiconductor Materials & Equipment sub-industry.
- Silicon carbide power device demand fuels high-energy ion implanter revenue growth
- Electric vehicle market expansion drives power semiconductor manufacturing equipment sales
- Geopolitical trade restrictions impact equipment shipments to Chinese chip manufacturers
- Mature process node investment cycles dictate long-term capital equipment order book
- Aftermarket service and parts revenue provides recurring high-margin cash flow stability
| Net Income: 100.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -2.73 > 1.0 |
| NWC/Revenue: 86.55% < 20% (prev 95.36%; Δ -8.80% < -1%) |
| CFO/TA 0.07 > 3% & CFO 96.6m > Net Income 100.9m |
| Net Debt (-324.6m) to EBITDA (133.5m): -2.43 < 3 |
| Current Ratio: 4.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.0m) vs 12m ago -4.19% < -2% |
| Gross Margin: 43.61% > 18% (prev 44.61%; Δ -1.00% > 0.5%) |
| Asset Turnover: 62.28% > 50% (prev 71.46%; Δ -9.19% > 0%) |
| Interest Coverage Ratio: 10.79 > 6 (EBIT TTM 115.8m / Interest Expense TTM 10.7m) |
| A: 0.53 (Total Current Assets 935.7m - Total Current Liabilities 203.9m) / Total Assets 1.37b |
| B: 0.37 (Retained Earnings 512.8m / Total Assets 1.37b) |
| C: 0.09 (EBIT TTM 115.8m / Avg Total Assets 1.36b) |
| D: 3.17 (Book Value of Equity 1.04b / Total Liabilities 329.9m) |
| Altman-Z'' = 8.61 = AAA |
| DSRI: 1.11 (Receivables 161.8m/164.9m, Revenue 845.4m/958.1m) |
| GMI: 1.02 (GM 44.61% / 43.61%) |
| AQI: 2.63 (AQ_t 0.25 / AQ_t-1 0.09) |
| SGI: 0.88 (Revenue 845.4m / 958.1m) |
| TATA: 0.00 (NI 100.9m - CFO 96.6m) / TA 1.37b) |
| Beneish M = -2.03 (Cap -4..+1) = BB |
As of June 12, 2026, the stock is trading at USD 157.43 with a total of 811,533 shares traded.
Over the past week, the price has changed by -1.11%,
over one month by -4.63%,
over three months by +83.44% and
over the past year by +122.48%.
Axcelis Technologies has received a consensus analysts rating of 3.60. Therefore, it is recommended to hold ACLS.
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 161 | 2.3% |
P/E Trailing = 45.7019
P/E Forward = 39.0625
P/S = 5.3496
P/B = 4.3295
P/EG = 1.4493
Revenue TTM = 845.4m USD
EBIT TTM = 115.8m USD
EBITDA TTM = 133.5m USD
Long Term Debt = 40.8m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 1.65m USD (from shortTermDebt, last quarter)
Debt = 42.0m USD (from shortLongTermDebtTotal, last quarter) (leases 42.0m already included)
Net Debt = -324.6m USD (calculated: Debt 42.0m - CCE 366.6m)
Enterprise Value = 4.20b USD (4.52b + Debt 42.0m - CCE 366.6m)
Interest Coverage Ratio = 10.79 (Ebit TTM 115.8m / Interest Expense TTM 10.7m)
EV/FCF = 47.45x (Enterprise Value 4.20b / FCF TTM 88.5m)
FCF Yield = 2.11% (FCF TTM 88.5m / Enterprise Value 4.20b)
FCF Margin = 10.46% (FCF TTM 88.5m / Revenue TTM 845.4m)
Net Margin = 11.93% (Net Income TTM 100.9m / Revenue TTM 845.4m)
Gross Margin = 43.61% ((Revenue TTM 845.4m - Cost of Revenue TTM 476.8m) / Revenue TTM)
Gross Margin QoQ = 40.50% (prev 46.97%)
Tobins Q-Ratio = 3.05 (Enterprise Value 4.20b / Total Assets 1.37b)
Interest Expense / Debt = 25.58% (Interest Expense 10.7m / Debt 42.0m)
Taxrate = 12.88% (14.9m / 115.8m)
NOPAT = 100.9m (EBIT 115.8m * (1 - 12.88%))
Current Ratio = 4.59 (Total Current Assets 935.7m / Total Current Liabilities 203.9m)
Debt / Equity = 0.04 (Debt 42.0m / totalStockholderEquity, last quarter 1.04b)
Debt / EBITDA = -2.43 (Net Debt -324.6m / EBITDA 133.5m)
Debt / FCF = -3.67 (Net Debt -324.6m / FCF TTM 88.5m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.43% (Net Income 100.9m / Total Assets 1.37b)
RoE = 9.79% (Net Income TTM 100.9m / Total Stockholder Equity 1.03b)
RoCE = 10.81% (EBIT 115.8m / Capital Employed (Equity 1.03b + L.T.Debt 40.8m))
RoIC = 8.93% (NOPAT 100.9m / Invested Capital 1.13b)
WACC = 13.88% (E(4.52b)/V(4.56b) * Re(13.80%) + D(42.0m)/V(4.56b) * Rd(25.58%) * (1-Tc(0.13)))
Discount Rate = 13.80% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: -100.00 | Cagr: -2.81%
[DCF] Terminal Value 55.45% ; FCFF base≈102.2m ; Y1≈89.7m ; Y5≈72.4m
[DCF] Fair Price = 30.56 (EV 614.4m - Net Debt -324.6m = Equity 939.1m / Shares 30.7m; r=13.88% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -85.82 | EPS CAGR: -15.80% | SUE: 0.06 | # QB: 0
Revenue Correlation: -86.61 | Revenue CAGR: -10.65% | SUE: 0.61 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.89 | Chg30d=+9.61% | Revisions=+20% | Analysts=3
EPS next Quarter (2026-09-30): EPS=1.05 | Chg30d=+5.73% | Revisions=-20% | Analysts=3
EPS current Year (2026-12-31): EPS=3.83 | Chg30d=+5.16% | Revisions=+20% | GrowthEPS=-21.5% | GrowthRev=+0.4%
EPS next Year (2027-12-31): EPS=4.64 | Chg30d=+2.75% | Revisions=-20% | GrowthEPS=+21.0% | GrowthRev=+9.4%
[Analyst] Revisions Ratio: +20%